Medincell SA is a renowned pharmaceutical company committed to innovation and research. With a strong focus on improving patients' lives, Medincell SA values integrity, excellence, and collaboration. The company's corporate philosophy revolves around delivering advanced drug delivery solutions and enhancing therapies. Medincell SA strives to develop partnerships and build a global network to accelerate the development and commercialization of its proprietary products. By integrating technology, science, and patient needs, Medincell SA aims to revolutionize drug delivery, offering sustainable and patient-centric solutions. Through its unwavering dedication to innovation and patient care, Medincell SA sets itself apart in the pharmaceutical industry.

Medincell SA is primarily present in France and the United States.

Medincell SA has attained several notable milestones. Its most significant achievements include successful clinical trials for their long-acting injectable formulations, regulatory approvals for key products, and collaborations with reputed pharmaceutical companies. Notably, the company secured FDA approval for a long-acting antipsychotic treatment, MedinCell's Atrigenic, marking a significant milestone in the field of mental health therapeutics. Additionally, Medincell SA forged strategic partnerships with renowned pharmaceutical giants, enabling them to expand their reach and leverage their innovative drug delivery technologies. With these achievements, Medincell SA has established itself as a pioneering force in the pharmaceutical industry, driving advancements in long-acting drug formulations.

Medincell SA is a pharmaceutical company specializing in controlled release drug delivery technologies. Founded in 2011, Medincell focuses on developing innovative therapeutic products to enhance treatment efficacy and patient adherence. The company is headquartered in Jacou, France, and operates with a team of experienced professionals dedicated to improving drug delivery systems. Medincell SA aims to revolutionize the pharmaceutical industry by offering sustained drug release solutions that provide targeted and continuous therapeutic effects. With a commitment to scientific excellence and advanced technologies, Medincell SA continues to make significant strides in the field of controlled release drug delivery.

The main competitors of Medincell SA in the market include pharmaceutical companies such as GlaxoSmithKline, Novartis, and Johnson & Johnson. These companies also specialize in developing and manufacturing innovative drug delivery technologies and products. Medincell SA faces competition in the market due to the constant need for advancements and solutions in the pharmaceutical industry.

Medincell SA is primarily active in the pharmaceutical industry.

Medincell SA is a pharmaceutical company focusing on the development of long-acting injectable drug delivery systems. Their business model revolves around pioneering technology to create innovative products for controlled release of medicines. Medincell SA aims to enhance patient care by offering sustained-release formulations, providing a more convenient and effective treatment option. By leveraging their proprietary BEPO technology, Medincell SA aims to address therapeutic challenges and optimize drug delivery to improve clinical outcomes. With a dedication to research and development, Medincell SA aims to revolutionize the pharmaceutical industry and contribute to the advancement of patient healthcare.

Medincell P/E suhe on −17,28.

Medincell KUV on 47,89.

AlleAktien kvaliteediskoor ettevõttele Medincell on 4/10.

Medincell käive on 9,03 mln. EUR.

Medincell kasum on −25,04 mln. EUR.

Medincell SA is a pharmaceutical company based in France that specializes in the development and marketing of long-acting drugs. The company is known for its groundbreaking technologies that allow for the release of medications into the body, resulting in a duration of up to three months. Medincell focuses on developing drugs for chronic diseases that require regular, long-term treatment. The company is composed of several business units that focus on different aspects of drug development and marketing. The research and development area is the core of Medincell, where the company develops its groundbreaking technologies and drug formulations. Medincell has a pipeline of projects aimed at developing long-acting drugs for use in chronic diseases. Another key area of Medincell is the manufacturing and marketing of its products. The company will not sell its products directly to end consumers, but rather to pharmaceutical companies, hospitals, or medical practices that will then prescribe them to patients. This allows Medincell to focus on developing high-quality, patient-oriented products without having to worry about direct marketing and distribution. Another important business area for Medincell is collaboration and partnerships with other pharmaceutical companies. Medincell has entered into a strategic partnership with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop a novel long-acting antipsychotic. In addition, the company has also entered into a collaboration with Pharmaserv Alliance to market its products in the United Arab Emirates and Saudi Arabia. Medincell is also advancing the development of its technology platform. The company is working on developing new release technologies for various types of drugs, including DNA-based therapeutics and cancer drugs. These technologies are intended to make medications even more effective and safer. In addition to the development and marketing of long-acting drugs, Medincell is also working on other solutions for the healthcare industry. These include innovative technologies for the administration of diabetes medications or the treatment of chronic pain. Overall, Medincell SA has an impressive and promising business strategy for the field of long-acting drug development. With innovative technologies, forward-thinking partnerships, and a clear focus on the needs of patients, the company expects to be successful in the future.

Medincell maksab dividendi 0 EUR, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Medincell jaoks arvutada või ettevõte ei maksa dividende välja.

Medincell ISIN on FR0004065605.

Medincell WKN on A2N6VA.

Medincell tähis on MEDCL.PA.

Viimase 12 kuu jooksul maksis Medincell dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Medincell tõenäoliselt dividendi summas 0 EUR.

Medincell praegune dividenditootlus on .

Medincell maksab kvartaalset dividendi. See makstakse välja kuudel .

Medincell maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 EUR. See vastab dividenditootlusele 0 %.

Medincell on liigitatud sektorisse 'Tervis'.

Viimase Medincell dividendide saamiseks 4.11.2024 suuruses 0 EUR pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 4.11.2024.

Viimane dividendimakse toimus 4.11.2024.

Aastal 2023 maksis Medincell 0 EUR dividende.

Medincell dividendid makstakse välja EUR.